Moderna Inc
NASDAQ:MRNA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.85
166.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Moderna Inc
Moderna Inc
Cash from Operating Activities
Moderna Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Operating Activities
-$3.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$7.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
-$842.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
Moderna Inc
Glance View
In the vibrant world of biotechnology, Moderna Inc. stands as a remarkable testament to the fusion of cutting-edge science and swift innovation. Founded in 2010 and based in Cambridge, Massachusetts, Moderna has crafted its niche in messenger RNA (mRNA) technology, pivoting the traditional paradigms of drug development. The company’s unique approach utilizes synthetic mRNA to direct cells in the body to produce proteins that can prevent, treat, or cure diseases. This innovative platform enables rapid testing and development of medicines across a wide array of therapeutic areas, from infectious diseases to oncology, leveraging its flexible technology to address significant unmet medical needs. Moderna’s story gained global prominence in the context of the COVID-19 pandemic, when its vaccine, one of the first to be authorized, became crucial in combatting the virus, highlighting the potential of mRNA technology on a global stage. Financially, Moderna’s business model is driven by a combination of strategic partnerships, robust research and development capabilities, and the commercialization of its mRNA products. The company collaborates extensively with government agencies, global health organizations, and biopharmaceutical enterprises to both advance its pipeline and maximize its market reach. Revenue is primarily generated through the sale of its COVID-19 vaccine, alongside income from grants and collaboration agreements. Moreover, Moderna continually invests in expanding its mRNA platform and portfolio, seeking long-term value creation by targeting diverse therapeutic areas such as rare diseases, autoimmune disorders, and personalized cancer vaccines. By reinvesting in innovation and scaling its manufacturing capabilities, Moderna is not just a quintessential biotech enterprise but a harbinger of a new era in medical science.
See Also
What is Moderna Inc's Cash from Operating Activities?
Cash from Operating Activities
-3.2B
USD
Based on the financial report for Sep 30, 2024, Moderna Inc's Cash from Operating Activities amounts to -3.2B USD.
What is Moderna Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-48%
Over the last year, the Cash from Operating Activities growth was -54%.
You don't have any saved screeners yet
